Morningstar

Eli Lilly's Omvoh Hits Goal in Phase 3 Study in Children With Ulcerative Colitis

Provided by Dow Jones

By Colin Kellaher 




  Eli Lilly said a late-stage study of Omvoh met its main goal in children with ulcerative colitis, one of the most common types of inflammatory bowel disease. 



  Eli Lilly on Monday said 81% of patients achieved clinical response to Omvoh induction at week 12 in the Phase 3 study in children ages 6 to 17 with moderately to severely active ulcerative colitis, including clinical, symptomatic and endoscopic outcomes. 



  The Indianapolis drugmaker said that among responders, 50% achieved clinical remission at 52 weeks, meeting the study's primary endpoint. 



  Eli Lilly said it plans to submit the study data to global regulators to support a potential label expansion for Omvoh, which is currently approved for adults with moderately to severely active ulcerative colitis. 





  Write to Colin Kellaher at colin.kellaher@wsj.com 





  (END) Dow Jones Newswires



  October 19, 2026 06:50 ET (10:50 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
Are TIPS ETFs the Best Way to Fight Inflation?
 
Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing. 
 
 
Daniel Sotiroff and Ivanna Hampton 
 
 
 
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
 
Even with significant growth potential, the stock’s lofty valuation is difficult to justify. 
 
 
Sean Dunlop, CFA 
 
 
 
10 Best Blue-Chip Stocks to Buy for the Long Term
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
33 Undervalued Stocks to Buy Before the Market Shifts Again
 
Here’s the new list of Morningstar’s top analyst picks for the fourth quarter of 2026. 
 
 
Susan Dziubinski and Tori Brovet 
 
 
 
 

			Sponsor Center